Gritstone to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Gritstone bio, Inc. (Nasdaq: GRTS), a biotech firm focused on cancer and infectious disease immunotherapies, will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 10:30 a.m. ET. CEO Andrew Allen will discuss company advancements, including its innovative Gritstone EDGE™ platform for predicting antigens to empower the immune system. Gritstone's lead programs include GRANITE for personalized cancer treatment and CORAL for a next-generation COVID-19 vaccine, alongside collaborations with health organizations and Gilead Sciences.
- None.
- None.
EMERYVILLE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021, at 10:30 a.m. ET.
A webcast will be available within the Investors & Media section of the Gritstone website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.
About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstonebio.com.
Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
Investors:
Alexandra Santos
Wheelhouse Life Science Advisors
(510) 871-6161
asantos@wheelhouselsa.com
FAQ
What is Gritstone bio presenting at the Goldman Sachs conference?
Who will present for Gritstone bio at the Goldman Sachs conference?
What innovative platforms does Gritstone bio use for immunotherapy development?
What are the lead programs developed by Gritstone bio?
What collaborations does Gritstone bio have for vaccine development?
